Creative Biolabs supports microbiome scientists worldwide with end-to-end Roseburia intestinalis Microbiome CRO Service, from strict anaerobic cultivation and functional characterization to formulation, in vitro host interaction studies, and preclinical-ready process development for live biotherapeutic product–oriented research programs.
Biotech, pharma, and academic groups rely on Creative Biolabs for robust R. intestinalis workflows and reproducible datasets.
R. intestinalis is a key butyrate-producing commensal enriched in the healthy colon and reduced in multiple chronic conditions, including inflammatory bowel disease, colorectal cancer, cardiometabolic disorders, and systemic immune dysregulation. Studies show that R. intestinalis shapes intestinal barrier integrity, immune cell polarization, and host metabolism through butyrate, flagellin–TLR5 signaling, and extracellular vesicles, positioning it as a high-value target for next-generation microbiome intervention research.
Creative Biolabs provides an integrated R. intestinalis Microbiome CRO Service to help you culture, characterize, and formulate this strict anaerobe under controlled conditions while generating mechanistic data aligned with your discovery, MoA, and LBP development goals.
Creative Biolabs isolates R. intestinalis from fecal or synthetic community samples using strict anaerobic workflows, selective media, and high-throughput colony screening. R. intestinalis candidates are prioritized based on butyrate production, genomic stability, and phenotypes aligned with your microbiome research objectives.
Our team confirms R. intestinalis identity by 16S rRNA gene sequencing, whole-genome sequencing, and targeted qPCR, supported by curated reference databases. This ensures that R. intestinalis strains entering downstream studies are accurately classified, genetically characterized, and fully traceable for regulatory-ready documentation.
R. intestinalis efficiently ferments complex plant polysaccharides and β-mannans into short-chain fatty acids, especially butyrate. Creative Biolabs quantifies R. intestinalis carbohydrate utilization profiles across tailored fiber panels, SCFA outputs, and pH shifts, providing mechanistic insight into diet–microbe interactions and substrate selection for formulation design.
We design R. intestinalis functional and mechanism-of-action assays to interrogate butyrate production, gene expression changes, and signaling readouts in disease-relevant in vitro systems. Using omics, reporter assays, and immune co-cultures, Creative Biolabs links R. intestinalis exposure to host pathways such as NF-κB, TLR5, tight junction regulation, and T cell modulation.
Our host–microbe interaction tests examine how R. intestinalis affects epithelial barriers, mucus production, and cytokine release. We use transwell intestinal monolayers, co-culture systems, and barrier integrity assays (e.g., TEER, FITC-dextran flux) to quantify how R. intestinalis–derived metabolites and surface components modulate permeability and junctional protein expression.
Creative Biolabs offers in vitro immune assays to measure how R. intestinalis regulates dendritic cells, macrophages, and T cells. We evaluate Treg differentiation, CD8⁺ T cell activation, cytokine profiles, and pattern-recognition receptor signaling using conditioned media, purified metabolites, or R. intestinalis–derived extracellular vesicles in well-controlled co-culture models.
R. intestinalis requires strict anaerobic, fine-tuned fermentation conditions to maintain viability and metabolite output. Creative Biolabs scales R. intestinalis cultures from lab flasks to bioreactors, optimizing parameters such as pH, redox potential, fiber substrates, and gas composition to deliver high-density biomass and consistent butyrate profiles for downstream research.
Our formulation scientists transform R. intestinalis cultures into research-grade preparations suitable for in vivo and in vitro studies. We assess excipients, cryoprotectants, encapsulation strategies, and storage conditions to preserve R. intestinalis viability, genetic stability, and functional traits within your required dosing and handling specifications.
Define R. intestinalis strain needs, models, endpoints, and regulatory expectations together with Creative Biolabs.
Isolate or onboard R. intestinalis, then verify identity, genome, and safety-relevant attributes.
Establish customized fermentative, host interaction, or immune assays optimized for R. intestinalis.
Run experiments, refine conditions, and adjust readouts based on interim data and study goals.
Deliver curated datasets, statistics, and interpretive reports aligned with your internal decision-making.
Transition R. intestinalis workflows toward larger-scale fermentation and stable formulations.
Long-standing experience with oxygen-sensitive live biotherapeutic candidates.
Programs optimized around MoA, not just high-level phenotypes.
Mix-and-match isolation, assays, and fermentation as your pipeline evolves.
Study plans and reports designed with future filings in mind.
Microbiologists, immunologists, and formulation experts collaborate end-to-end.
Transparent project management for clients across time zones and regions.
Roseburia intestinalis was one of the three target strains produced in this lab-scale project, formulated as lyophilized powder for oral gavage in mice. With a final yield of 6.2×10^8 CFU per vial, the strain was cultured anaerobically, carefully monitored for purity, and processed through optimized harvesting and lyophilization steps. The dosing regimen (10^8 CFU/mouse/day) supported studies aiming to restore gut dysbiosis caused by depletion of this key butyrate-producing commensal. This work enabled controlled in-vivo evaluation of R. intestinalis in microbiota-driven immune and metabolic modulation.
Fig.1 Gram staining of R. intestinalis.
R. intestinalis research in colitis models shows improved tight junction expression, reduced pro-inflammatory mediators, and stabilized permeability, supporting its use as a tool species to study epithelial barrier regulation and immune crosstalk in chronic intestinal inflammation.
Preclinical work links reduced R. intestinalis abundance to colorectal cancer, while R. intestinalis–derived butyrate enhances epithelial barrier function and modulates CD8⁺ T cell cytotoxicity, enabling detailed investigation of microbiome influence on tumor biology and response to PD-1 pathway blockade in research settings.
Diet–microbiome studies demonstrate that colonization with R. intestinalis reshapes lipid metabolism, decreases endotoxemia, and reduces atherosclerotic lesion development in mouse models, providing a powerful platform to explore gut–vascular axes and SCFA-driven modulation of vascular inflammation.
R. intestinalis has been associated with improved insulin sensitivity and reduced metabolic inflammation in experimental systems, connecting butyrate signaling and barrier protection to models of obesity, type 2 diabetes, and fatty liver pathophysiology that Creative Biolabs can help interrogate.
Through effects on Treg differentiation, dendritic cells, and macrophage polarization, R. intestinalis is increasingly studied in systemic autoimmunity and inflammatory syndromes, supporting biomarker discovery and microbiome modulation strategies in immune-driven disease models.
Emerging work on R. intestinalis–derived extracellular vesicles and strain-level signatures positions this bacterium as both a functional modulator and a potential biomarker of gut ecosystem health. Creative Biolabs supports EV isolation, characterization, and functional testing in line with your discovery needs.
Below is the key product information for the available R. intestinalis strain.
| Product Name | Catalog No. | Target | Product Overview | Size | Price |
|---|---|---|---|---|---|
| Roseburia intestinalis; 14610 | LBSX-0522-GF42 | Roseburia | A saccharolytic, butyrate-producing bacterium first isolated from infant faeces. It is anaerobic, gram-positive, non-sporeforming, slightly curved rod-shaped and motile by means of multiple subterminal flagella. | — | Inquiry |
Our platform supports discovery, mechanism-of-action, formulation feasibility, and LBP-oriented preclinical studies where R. intestinalis is used as a model strain to interrogate barrier function, immune modulation, metabolism, or microbiome–drug interactions.
We culture R. intestinalis in dedicated anaerobic chambers and bioreactors with continuous monitoring of oxygen, redox potential, and pH, ensuring stable growth, reproducible SCFA profiles, and minimal stress during sampling, processing, and downstream assay integration.
Yes. Our team designs synthetic communities where R. intestinalis is combined with complementary strains. We track each member by strain-specific qPCR, sequencing, and metabolite profiling to capture consortia stability and functional outputs over time.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2025 Creative Biolabs. All Rights Reserved.